Sequential methotrexate–5-fluorouracil treatment of squamous cell carcinoma of the head and neck
- 15 September 1983
- Vol. 52 (6) , 971-973
- https://doi.org/10.1002/1097-0142(19830915)52:6<971::aid-cncr2820520606>3.0.co;2-b
Abstract
Thirty-six patients with squamous cell carcinoma of the head and neck were treated with sequential methotrexate–5-fluorouracil followed by leucovorin rescue. The frequency of objective tumor regression obtained was 64% (complete response + partial response) with 19% complete regression. In 20 not previously treated patients, the objective response rate was 70%. Approximately the same result was obtained for tumors of different anatomical sites of the head and neck. The degree of differentiation of the squamous cell carcinoma did not seem to be of prognostic importance for the initial tumor response. Toxicity was very mild and usually disappeared when the interval between the chemotherapy courses was prolonged from 1 to 2 weeks. Radiotherapy could be added sequentially to the treatment without measurable escalated toxicity.This publication has 4 references indexed in Scilit:
- Preliminary report on the efficacy of sequential methotrexate and 5-fluorouracil in advanced breast cancerCancer, 1981
- Enhanced 5-Fluorouracil Nucleotide Formation After Methotrexate Administration: Explanation for Drug SynergismScience, 1979
- Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylateBiochemistry, 1974
- Treatment of carcinoma of the head and neck with intravenous methotrexateCancer, 1968